Halozyme Therapeutics Inc HALO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
39.82UNCH (UNCH)
Volume
45,914
Close
39.82quote price arrow up+0.52 (+1.32%)
Volume
786,260
52 week range
29.85 - 45.00
Loading...
  • Open39.56
  • Day High40.74
  • Day Low38.88
  • Prev Close39.30
  • 52 Week High45.00
  • 52 Week High Date08/10/23
  • 52 Week Low29.85
  • 52 Week Low Date05/09/23

Key Stats

  • Market Cap5.059B
  • Shares Out127.05M
  • 10 Day Average Volume0.77M
  • Dividend-
  • Dividend Yield-
  • Beta1.25
  • YTD % Change7.74

KEY STATS

  • Open39.56
  • Day High40.74
  • Day Low38.88
  • Prev Close39.30
  • 52 Week High45.00
  • 52 Week High Date08/10/23
  • 52 Week Low29.85
  • 52 Week Low Date05/09/23
  • Market Cap5.059B
  • Shares Out127.05M
  • 10 Day Average Volume0.77M
  • Dividend-
  • Dividend Yield-
  • Beta1.25
  • YTD % Change7.74

RATIOS/PROFITABILITY

  • EPS (TTM)2.11
  • P/E (TTM)18.88
  • Fwd P/E (NTM)10.81
  • EBITDA (TTM)422.43M
  • ROE (TTM)222.07%
  • Revenue (TTM)829.253M
  • Gross Margin (TTM)76.80%
  • Net Margin (TTM)33.96%
  • Debt To Equity (MRQ)1,788.91%

EVENTS

  • Earnings Date05/07/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Halozyme Therapeutics Inc

 

Profile

MORE
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and...
Jeffrey Henderson
Independent Chairman of the Board
Helen Torley
President, Chief Executive Officer, Director
Nicole Labrosse
Chief Financial Officer, Senior Vice President
Address
12390 EL CAMINO REAL
San Diego, CA
92130
United States

Top Peers

SYMBOLLASTCHG%CHG
CRSP
CRISPR Therapeutics AG
55.07+1.26+2.34%
TXG
10X Genomics Inc
26.29-0.63-2.34%
ACAD
ACADIA Pharmaceuticals Inc
17.08+0.03+0.18%
RARE
Ultragenyx Pharmaceutical Inc
43.20-0.10-0.23%
APLS
Apellis Pharmaceuticals Inc
47.49+1.44+3.13%